'Whereas most new cancer drugs afford modest benefits,2approved drugs or those in development may be heralded as “game changers” or “breakthroughs” in the lay press. These news articles may be important sources of information to patients, the public, and investors—with a broader reach than medical journal articles. However, omission of medical context or use of inflated descriptors may lead to misunderstandings among readers.'

https://docteur.nicoledelepine.fr/the-use-of-superlatives-in-cancer-research/